Navigation Links
Drug pair cuts children's urinary infections up to 80 percent

Long-term use of a drug combination reduces the risk of recurrent urinary tract infection by up to 80 percent in children with the urinary condition vesicoureteral reflux compared to placebo, according to research funded by the National Institutes of Health. Results were published online May 4 in the New England Journal of Medicine to coincide with presentation at the Pediatric Academic Societies Annual Meeting in Vancouver, British Columbia.

In vesicoureteral reflux (VUR), developmental abnormalities in one or both ureters -- tubes connecting the kidneys with the bladder -- allow urine to flow back from the bladder into the ureters, and sometimes into the kidneys. VUR is found in 30-40 percent of children who have had a UTI, and is one of the most common urinary tract problems in children.

The risk of recurrent infection was cut by 50 percent in children with VUR using the drug combination trimethoprim/sulfamethoxazole (TMP/SMZ). Children with VUR and bladder and bowel dysfunction saw the greatest reduction, up to an 80 percent lower risk of recurrent infections. This group is also more likely to have recurrent urinary infections, which can increase the risk of kidney scarring and the potential for kidney failure.

For decades, doctors have treated children who have VUR with a small daily dose of TMP/SMZ often for years, in hopes of preventing recurrent UTIs and kidney damage. The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial provides the first conclusive clinical evidence for the effectiveness of this practice. It studied a well-defined population of children compared to earlier studies, included a placebo group, used digital imaging, and showed a strong response to treatment.

"We are looking deeper into the data from the RIVUR trial to gain further insight into other factors that may reduce susceptibility to recurrent infections and scarring," said Dr. Marva Moxey-Mims, a pediatric kidney specialist at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases, the study's primary funder. "In the meantime, we can buy children some time with fewer infections, allowing many of them to outgrow reflux as their bodies develop and mature."

While TMP/SMZ significantly reduced recurrent infections, the number of children who developed kidney scarring did not drop. The researchers suggest this may be due to parents' heightened vigilance for UTI symptoms and early treatment in the trial and that most of the children were enrolled after their first infection rather than after multiple infections, when more scarring might occur.

"We also saw some increased antimicrobial resistance, which researchers are looking at more closely," Moxey-Mims said. "However, until we have those results, the use of these drugs appears to provide more benefit than risk in these children."

RIVUR was a two-year clinical trial that randomized 607 children to receive the TMP/SMP drug combination or placebo. The study was conducted in 19 locations across the United States and coordinated by the University of North Carolina at Chapel Hill. General information about clinical studies in children can be found at


Contact: Bill Polglase
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Related medicine news :

1. CHOC researchers identify technique to reduce childrens post-op pain after high-risk surgery
2. Vibrant Nutraceuticals Announces Launch of Vegan Childrens’ Probiotic, KidsLac
3. Impact of battlefield-related genitourinary injuries described in Journal of Mens Health
4. Dance and virtual reality: A promising treatment for urinary incontinence in elderly women
5. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
6. Urinary Tract Infection Market (UTI): Gram-Negative Bacterial 2022 Epidemiology Forecasts in New Research Report at
7. Minimally Invasive Urethral Sling Procedure Treats Urinary Incontinence; Consultations Now Available at Women’s Excellence's New Location Near Berkley, Michigan
8. Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
9. New study: Enterocystoplasty in children with genitourinary abnormalities is safe and effective
10. Macrophage-derived mediators may have potential as biomarkers for urinary stone risk
11. J. William Groves, Jr. MD, FACOG, Receives InTone Specialist Certification to Treat Female Urinary Incontinence from InControl Medical, LLC
Post Your Comments:
Related Image:
Drug pair cuts children's urinary infections up to 80 percent
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology: